USPTO Examiner WELLS LAUREN QUINLAN - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18985720DITHIENYL DISULFIRAM DERIVATIVES AS SELECTIVE ALDH1A1 INHIBITORSDecember 2024May 2025Allow510YesNo
18812527MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOFAugust 2024March 2025Allow711YesNo
18652993RAMIPRIL SOLUTION FOR ORAL DOSAGEMay 2024May 2025Allow1221YesNo
18591969CRYSTALLINE SALTS OF PSILOCINFebruary 2024March 2025Allow1201YesNo
18591925CRYSTALLINE SALTS OF PSILOCINFebruary 2024March 2025Allow1201YesNo
18685899ABIRATERONE PRECURSOR COMPOUND AND PREPARATION METHOD AND USE THEREOFFebruary 2024June 2025Allow1621YesNo
18529689TEAD INHIBITORS AND METHODS OF USES THEREOFDecember 2023April 2024Allow501YesNo
18278628PHARMACEUTICAL COMPOSITION OF FORSKOLIN-ISOFORSKOLIN AND PENTACYCLIC TRITERPENOID COMPOUND, AND APPLICATION THEREOFOctober 2023June 2025Abandon2221NoNo
18480898RUXOLITINIB FOR THE TREATMENT OF PRURIGO NODULARISOctober 2023March 2025Abandon1710NoNo
18344336RIBOCIL C ANTIBIOTICS EFFECTIVE FOR GRAM-NEGATIVE PATHOGENSJune 2023August 2024Allow1401YesNo
18344555POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4June 2023December 2024Abandon1701NoNo
18340006METHODS OF PROVIDING SOLRIAMFETOL THERAPY TO SUBJECTS WITH IMPAIRED RENAL FUNCTIONJune 2023November 2023Allow410NoNo
18337623PRODUCTION METHOD FOR RADIOLABELED ARYL COMPOUNDJune 2023June 2025Allow2321YesNo
18208025METHOD FOR DIFFERENTIALLY DIAGNOSING ACTH-DEPENDENT CUSHING'S SYNDROMEJune 2023October 2024Abandon1601NoNo
18202681SELECTIVE DETECTION OF BED BUGSMay 2023March 2025Allow2111YesNo
18311126STABLE LIQUID VIGABATRIN PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGEMay 2023May 2024Allow1201YesNo
18304270PHOSPHOLIPID COMPOUNDS AND USES THEREOFApril 2023February 2024Allow1011YesNo
18300312COMBINATION THERAPY FOR PI3K-ASSOCIATED DISEASE OR DISORDERApril 2023November 2024Abandon1901NoNo
18129267Methods for the Prevention and Treatment of Hearing Loss using OseltamivirMarch 2023April 2024Allow1311YesNo
18128075COMPOSITIONS AND METHODS FOR TREATING RENAL INJURYMarch 2023February 2025Abandon2311NoNo
18184618DIETARY CHOLINE SUPPLEMENTATION TO REDUCE TUMOR VOLUME AND ENHANCE COGNITIVE RESPONSE DURING CANCER TREATMENTMarch 2023July 2024Abandon1711NoNo
18160897COMPOSITIONS AND METHODS FOR INHIBITING CARP-1 BINDING TO NEMOJanuary 2023March 2024Abandon1401NoNo
18153954PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSUREJanuary 2023January 2024Abandon1201NoNo
18146698COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERSDecember 2022November 2024Allow2211YesNo
18146393COMPOSITIONS COMPRISING CAROTENOIDS, METHODS AND APPLICATION THEREOFDecember 2022February 2025Abandon2621YesNo
18063695USE OF TETRANDRINE IN COMBINATION WITH ALL-TRANS RETINOIC ACID IN PREPARATION OF MEDICAMENT FOR TREATING PNEUMOCONIOSISDecember 2022January 2025Abandon2521NoNo
18075163DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORSDecember 2022September 2024Allow2210YesNo
17992254FENFLURAMINE FOR TREATMENT OF CONDITIONS ASSOCIATED WITH SPREADING DEPOLARIZATIONNovember 2022January 2025Abandon3621NoNo
17985740TREATING LIVER DISORDERS WITH AN SSAO INHIBITORNovember 2022February 2025Abandon2821NoNo
17970933TOPICAL TRANEXAMIC ACID COMPOSITIONS AND METHODS OF USE THEREOFOctober 2022March 2023Allow510YesNo
17965569COMPOUNDS FOR TARGETED DEGRADATION OF BRD9October 2022November 2023Allow1311YesNo
17915123USE OF A THIENOPYRIDONE DERIVATIVE IN THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)September 2022March 2025Allow2931YesNo
17954319COMPOSITION FOR MODULATING HYDROGEN ION PHYSIOLOGY RELATED TO BRAIN HEALTH COMPONENTSeptember 2022August 2024Abandon2321YesNo
17934625PYRIDAZINESSeptember 2022December 2023Allow1421YesNo
17901775COMPOUNDS FOR TARGETED DEGRADATION OF BRD9September 2022February 2024Allow1810NoNo
17818846CRYSTALLINE FORM OF TOLEBRUTINIBAugust 2022March 2023Allow811YesNo
17807083METHODS AND COMPOSITIONS FOR TARGETING PD-L1June 2022February 2024Allow2011NoNo
17751998CRYSTALLINE SALTS OF PSILOCINMay 2022December 2023Allow1811YesNo
17752526USES OF A SOMATOSTATIN MODULATOR FOR THE TREATMENT OF DISEASEMay 2022October 2024Abandon2920NoNo
17749082PROPHYLAXIS AND REVERSAL OF STIMULANT AND OPIOID/OPIATE OVERDOSE AND/OR TOXIC EXPOSUREMay 2022August 2023Abandon1520NoNo
17736773IMPROVING THE QUALITY OF HUMAN OOCYTESMay 2022August 2024Abandon2721YesNo
17734601LSD AND PSILOCYBIN DOSE EQUIVALENCE DETERMINATIONMay 2022April 2025Abandon3631NoNo
17721789COMPOSITIONS AND METHODS FOR PROMOTING SLEEPApril 2022April 2024Abandon2411NoNo
17678990TREATMENT OF A RESPIRATORY CORONAVIRUS INFECTION WITH NITROXIDESFebruary 2022May 2023Abandon1520YesNo
17623477CAPACITATIVE CALCIUM ENTRY INHIBITORSDecember 2021June 2025Abandon4201NoNo
17545864COMPOSITIONS AND METHODS FOR REDUCING CANCER STEM CELL GROWTHDecember 2021March 2024Allow2740YesNo
17541035COMPOUNDS FOR TARGETED DEGRADATION OF BRD9December 2021May 2022Allow611NoNo
17540826DISULFIRAM DERIVATIVES AS ALDH1A1 AND MAGL INHIBITORSDecember 2021May 2023Allow1731YesYes
17595772DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORSNovember 2021May 2025Abandon4110NoNo
17515372METHOD FOR PRODUCING ORAL DISINTEGRATING FILM COMPRISING POORLY SOLUBLE DRUGOctober 2021April 2024Abandon2941YesNo
17607632METHODS OF TREATING PRURITUSOctober 2021June 2025Abandon4331YesNo
17502559PHOSPHOLIPID COMPOUNDS AND USES THEREOFOctober 2021September 2024Allow3531YesNo
17604371COMBINATION THERAPYOctober 2021December 2024Abandon3821NoNo
17503126LIQUID PHARMACEUTICAL COMPOSITIONSOctober 2021January 2024Abandon2710NoNo
174885682-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORSSeptember 2021December 2024Abandon3811NoNo
17440879NOVEL AZAINDOLE DERIVATIVESeptember 2021April 2025Abandon4310NoNo
17439611PKM2 MODULATORS AND METHODS FOR THEIR USESeptember 2021April 2025Abandon4301NoNo
17472647Method For Treating COVID-19 and Related Viral InfectionsSeptember 2021December 2023Abandon2721NoNo
17471922INTEGRIN AGONISTS OR ACTIVATING COMPOUNDS AND METHODS FOR MAKING AND USING SAMESeptember 2021June 2024Allow3341YesNo
17469178POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4September 2021November 2023Abandon2710NoNo
17465394CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERSSeptember 2021July 2023Abandon2201NoNo
17409258A METHOD FOR IMPROVING ANTICANCER EFFECT OF AN ANTICANCER DRUG FOR TREATING OR PREVENTING CANCERAugust 2021March 2024Abandon3121YesNo
17445483TREATMENT OF ENDOPLASMIC RETICULUM MEDIATED DISORDERS WITH ANILIDE DERIVATIVESAugust 2021October 2024Allow3821YesNo
17400164Synthesis of Anti-inflammatory and Anti-cancer Agents through Fungal Transformation of MiboleroneAugust 2021June 2023Abandon2201NoNo
17429791PHARMACEUTICAL COMPOSITION FOR CO-ADMINISTRATION OF ACIDOSIS-INDUCING DRUGAugust 2021May 2024Abandon3311NoNo
17427037METHODS AND COMPOSITIONS COMPRISING A 5HT RECEPTOR AGONIST FOR THE TREATMENT OF PSYCHOLOGICAL, COGNITIVE, BEHAVORIAL, AND/OR MOOD DISORDERSJuly 2021January 2023Abandon1700NoNo
17386339METHODS OF INHIBITING PROCOLLAGEN-LYSINE, 2-OXOGLUTARATE 5-DIOXYGENASE 2July 2021August 2024Abandon3730YesNo
17425629ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAMEJuly 2021May 2025Abandon4541YesNo
17381308METHODS FOR THE TREATMENT OF CONDITIONS RELATED TO HYDROGEN SULFIDEJuly 2021November 2023Allow2721YesNo
17365499Finished Pharmaceutical Dosage Form Of A Methenamine Salt Such As Methenamine MandelateJuly 2021January 2024Abandon3111NoNo
17361862METHOD TO PREVENT AND TREAT HEARING LOSS BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERSJune 2021January 2024Abandon3011NoNo
17362969Methods of Using Cannabinoid Compositions for Inducing and Promoting SleepJune 2021October 2023Abandon2711NoNo
17360466METHOD TO PREVENT AND TREAT GINGIVAL RECESSION BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERSJune 2021June 2024Abandon3611NoNo
17352737METHOD FOR DIFFERENTIALLY DIAGNOSING ACTH-DEPENDENT CUSHING'S SYNDROMEJune 2021November 2023Abandon2910NoNo
17416639COMPOUNDS AND METHODS FOR THE TREATMENT OF POLYCYSTIC KIDNEY DISEASE (PKD)June 2021March 2024Abandon3311NoNo
17414335PHENYLPYRROLIDINE COMPOUND AND USE THEREOFJune 2021November 2024Abandon4101NoNo
17347272MEDICAMENT, COMPOUND, COMPOSITION AND METHOD FOR TREATING HERPESJune 2021July 2023Abandon2510NoNo
17339468SUPPLEMENT INCLUDING GAMMA-AMINOBUTYRIC ACID FOR RESTORING GROWTH HORMONE LEVELSJune 2021July 2023Abandon2510NoNo
17299844STABLE LIQUID VIGABATRIN PHARMACEUTICAL COMPOSITION FOR ORAL DOSAGEJune 2021June 2023Allow2410YesNo
17298115AGONISTS OF PPAR-deltaMay 2021May 2023Allow2411YesNo
17297848COMPOSITIONS AND METHODS FOR MODULAR CONTROL OF BIOORTHOGONAL LIGATIONMay 2021October 2023Allow2911YesNo
17303397SMALL MOLECULE ACTIVATORS OF POLYCYSTIN-2 (PKD2) AND USES THEREOFMay 2021March 2023Abandon2101NoNo
17296968FURTHER HETEROAROMATIC COMPOUNDS HAVING ACTIVITY AGAINST RSVMay 2021October 2024Abandon4001NoNo
17295638METHODS FOR MANAGEMENT OF WEIGHTMay 2021January 2024Abandon3211NoNo
17294793ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF BIRTHMARKSMay 2021March 2025Allow4621NoNo
17320316CRENOLANIB FOR TREATING PDGFR ALPHA MUTATED PROLIFERATIVE DISORDERSMay 2021March 2023Abandon2201NoNo
17302777COMPOSITIONS FOR TREATING HAIR LOSSMay 2021August 2024Abandon4031NoNo
17292403METHODS OF TREATING SUBJECTS HAVING PLATELET DYSFUNCTION WITH IV MELOXICAMMay 2021November 2024Abandon4210NoNo
17307851SMALL MOLECULE ACTIVATORS OF INTERFERON REGULATORY FACTOR 3 AND METHODS OF USE THEREOFMay 2021August 2023Abandon2711NoNo
172891232-AMINO-N-HETEROARYL-NICOTINAMIDES AS NAV1.8 INHIBITORSApril 2021October 2024Abandon4201NoNo
17285849Identification of PPM1D mutations as a novel biomarker for NAMPTi sensitivityApril 2021April 2025Abandon4811NoNo
17232049NOVEL KV3 MODULATORSApril 2021March 2025Allow4721NoNo
17284824ANTIPSYCHOTIC AND USE THEREOFApril 2021April 2025Abandon4811NoNo
17283700GLUCOCORTICOID RECEPTOR MODULATORSApril 2021October 2022Abandon1901NoNo
17282401METHODS TO TREAT RENAL DISORDERS USING CALCIUM CHANNEL INHIBITORSApril 2021January 2025Abandon4611NoNo
17278880POLYMER-PARTICLE LIGHT-CLEAVABLE CARRIER SYSTEMS FOR PHOTODYNAMIC THERAPYMarch 2021March 2025Allow4821YesNo
17278103COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISORDERSMarch 2021August 2024Abandon4141YesNo
17278051METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCYMarch 2021January 2023Abandon2211NoNo
17205451ANTIVIRAL COMPOUNDS AND METHOD FOR TREATING HEPATOTROPIC VIRAL INFECTION, PARTICULARLY HEPATITIS B AND HEPATITIS DMarch 2021October 2023Abandon3120NoNo
17276543ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) NANO-FORMULATION OF COMPOUNDS AND METHODS OF USING THE SAMEMarch 2021February 2025Allow4721YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WELLS, LAUREN QUINLAN.

Strategic Value of Filing an Appeal

Total Appeal Filings
4
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
4
(100.0%)
Filing Benefit Percentile
0.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WELLS, LAUREN QUINLAN - Prosecution Strategy Guide

Executive Summary

Examiner WELLS, LAUREN QUINLAN works in Art Unit 1622 and has examined 184 patent applications in our dataset. With an allowance rate of 35.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.

Allowance Patterns

Examiner WELLS, LAUREN QUINLAN's allowance rate of 35.3% places them in the 3% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WELLS, LAUREN QUINLAN receive 1.80 office actions before reaching final disposition. This places the examiner in the 54% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WELLS, LAUREN QUINLAN is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +61.3% benefit to allowance rate for applications examined by WELLS, LAUREN QUINLAN. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 23.1% of applications are subsequently allowed. This success rate is in the 22% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.5% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 50.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 61.2% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.2% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.